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Novel antitumour agents
A new strategy has been described that combines the combinatorial synthesis of several
libraries and the testing of these compounds against 60 different cell-based antitumour screens
at the National Cancer Institute (J.R. Appel et al., Mol. Div., 4, (1999), 91-102). Five
different combinatorial libraries consisting of peptides, peptidomimetics, polyamines or small
molecules were initially prepared and tested against three representative cell lines to identify
the most active library types. Following this investigation, the search narrowed down to two
libraries based on N-perbenzylated pentamine structures (1) and N-acylated permethylated
triamines (2).
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The libraries were prepared on solid support using the ‘tea-bag’ method for simultaneous
multiple synthesis. The mixtures were generated by adding mixtures of building blocks using
ratios previously determined to give equimolar ratios of products. The N-perbenzylated
pentamines were constructed from a total of 52 building blocks giving a final library size of
7,311,616 compounds. The N-acylated permethylated triamines also used 52 monomers to
give a library size of 454,272 compounds. In each case the synthetic route employed a borane
reduction to reduce peptide intermediates to polyamines.
Active compounds were tested in mice to determine maximum tolerated dose, followed by
screening against human tumour cells cultivated in hollow fibres. Three compounds have been
identified that are currently being evaluated in human tumour xenografts.
--------------------------------------------------------------------------------------------------------------
Purine CDK inhibitors
Purines occur at relatively high concentrations in all living organisms where they play critical
roles as cofactors and signalling molecules modulating protein function. Furthermore, purines
have been a fruitful source of inhibitors of cyclin-dependent kinases (CDKs) - targets which
are especially attractive in the light of their key role in regulating the cell cycle. A recent
publication describes the use of both solution and solid-phase methods for the synthesis of
purine-based libraries and the results of screening these compounds against CDK (Y-T. Chang
et al., Chem. Biol., 6, (1999), 361-375).
Supporting purine precursors on solid-phase allowed the combinatorial variation of two
substituent positions. The effects of substituents in the 2,6, and 9 positions are additive and the
results of screening the binary libraries against starfish oocyte CDK1/cyclin B allowed the
identification of potent trisubstituted purine products. The most active compounds were
subsequently tested for their ability to inhibit growth of U937 human leukaemia cells. In
general the cell-based IC50 values were higher than the in vitro values, presumably as a result
of competition with high concentrations of intracellular ATP.
From the several hundred compounds prepared, several highly specific and potent CDK
inhibitors were identified. It was found that various purines act selectively on different
biochemical pathways affecting cell-cycle progression. For example compound (3) arrests the
cell cycle specifically in the G2 phase where as (4) induced M-phase arrest.
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Selective ACE inhibitors
Inhibitors of angiotensin converting enzyme (ACE) have been employed for many years as
effective treatments for hypertension, cardiac failure and diabetic nephropathy. These drugs
block the renin-angiotensin cascade and prevent the formation of the hypertensive peptide,
angiotensin II. Recently, it has been discovered that the two catalytic domains of ACE may
have slightly different functions. Possibly the N- domain might be responsible for the
breakdown of peptides such as acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), a negative
regulator of haematopoietic stem cell differentiation and proliferation.
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To define more fully the distinct roles of the two active sites, combinatorial chemistry has been
used to identify compounds that selectively inhibit the N- domain site (V. Dive et al., Proc.
Natl. Acad. Sci. USA, 96, (1999), 4330-4335). A library of phosphinic peptides has been used
to identify a compound (5) which can differentiate the two ACE active sites (N-domain site Ki
= 12 nM, C-domain site, Ki = 25 µM). Further studies with this compound may reveal the
contribution of the ACE N-domain active site to the break-down of AcSDKP.
